Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.

Jung-min Lee; Richard G. Moore; Sharad A. Ghamande; Min S. Park; John Paul Diaz; Julia A. Chapman; James Erasmus Kendrick; Brian M. Slomovitz; Krishnansu Sujata Tewari; Elizabeth S. Lowe; Tsveta Milenkova; Sanjeev Kumar; Mike Dymond; Iwanka Kozarewa; Joyce F. Liu

doi:10.1200/JCO.2020.38.15_SUPPL.6056

Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.

Jung-min Lee
, Richard G. Moore
, Sharad A. Ghamande
, Min S. Park
, John Paul Diaz
, Julia A. Chapman
, James Erasmus Kendrick
, Brian M. Slomovitz
, Krishnansu Sujata Tewari
, Elizabeth S. Lowe
, Tsveta Milenkova
, Sanjeev Kumar
, Mike Dymond
, Iwanka Kozarewa
, Joyce F. Liu

National Institutes of Health
University of Rochester
Georgia Regents University
Swedish Cancer Institute, Seattle, WA;
Miami Cancer Institute, Miami, FL;
University of Kansas
Advent Health Orlando, Orlando, FL;
University of Miami
University of California, Irvine
AstraZeneca
Harvard University

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	38
DOIs	https://doi.org/10.1200/JCO.2020.38.15_SUPPL.6056
State	Published - May 25 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2020.38.15_SUPPL.6056License: Unspecified

Cite this

Lee, J., Moore, R. G., Ghamande, S. A., Park, M. S., Diaz, J. P., Chapman, J. A., Kendrick, J. E., Slomovitz, B. M., Tewari, K. S., Lowe, E. S., Milenkova, T., Kumar, S., Dymond, M., Kozarewa, I., & Liu, J. F. (2020). Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial. Journal of Clinical Oncology, 38. https://doi.org/10.1200/JCO.2020.38.15_SUPPL.6056

Lee, J, Moore, RG, Ghamande, SA, Park, MS, Diaz, JP, Chapman, JA, Kendrick, JE, Slomovitz, BM, Tewari, KS, Lowe, ES, Milenkova, T, Kumar, S, Dymond, M, Kozarewa, I & Liu, JF 2020, 'Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.', Journal of Clinical Oncology, vol. 38. https://doi.org/10.1200/JCO.2020.38.15_SUPPL.6056

@article{90fda21db6114a369727fd0d61257238,

title = "Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.",

author = "Jung-min Lee and Moore, \{Richard G.\} and Ghamande, \{Sharad A.\} and Park, \{Min S.\} and Diaz, \{John Paul\} and Chapman, \{Julia A.\} and Kendrick, \{James Erasmus\} and Slomovitz, \{Brian M.\} and Tewari, \{Krishnansu Sujata\} and Lowe, \{Elizabeth S.\} and Tsveta Milenkova and Sanjeev Kumar and Mike Dymond and Iwanka Kozarewa and Liu, \{Joyce F.\}",

note = "6056 Background: A Phase I trial (NCT01116648) of cediranib (cedi) in combination with olaparib (ola) (cedi + ola) demonstrated an overall response rate of 44\% in patients (pts) with recurrent ovarian cancer (OC), including pts without a deleterious or suspected deleterious gBRCAm (non-gBRCAm; Liu et al. Eur J Cancer 2013).",

year = "2020",

month = may,

day = "25",

doi = "10.1200/JCO.2020.38.15\_SUPPL.6056",

language = "American English",

volume = "38",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.

AU - Lee, Jung-min

AU - Moore, Richard G.

AU - Ghamande, Sharad A.

AU - Park, Min S.

AU - Diaz, John Paul

AU - Chapman, Julia A.

AU - Kendrick, James Erasmus

AU - Slomovitz, Brian M.

AU - Tewari, Krishnansu Sujata

AU - Lowe, Elizabeth S.

AU - Milenkova, Tsveta

AU - Kumar, Sanjeev

AU - Dymond, Mike

AU - Kozarewa, Iwanka

AU - Liu, Joyce F.

N1 - 6056 Background: A Phase I trial (NCT01116648) of cediranib (cedi) in combination with olaparib (ola) (cedi + ola) demonstrated an overall response rate of 44% in patients (pts) with recurrent ovarian cancer (OC), including pts without a deleterious or suspected deleterious gBRCAm (non-gBRCAm; Liu et al. Eur J Cancer 2013).

PY - 2020/5/25

Y1 - 2020/5/25

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6056

U2 - 10.1200/JCO.2020.38.15_SUPPL.6056

DO - 10.1200/JCO.2020.38.15_SUPPL.6056

M3 - Article

VL - 38

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.

Disciplines

Access to Document

Other files and links

Cite this